Mexico Consuelo Albarrán, co-founder and CEO of DEFI Latina Healthcare, showcases the increasing added value brought by this leading Cofepris-authorized third party (ATP) to the pharmaceutical industry, the recent expansion of the company’s capacity into the biotech field, and its readiness to increase collaboration with both pharma companies and Cofepris to…
Switzerland Nicolas Hug reveals how UCB´s new facility in Bulle, Switzerland, is one of the largest microbial derived pharmaceuticals plants in Europe; how the key challenge for manufacturers today is to guarantee supplies by building a robust network; and why manufacturing is where dreams become reality, taking the results from a…
Mexico The university spin-off UDIBI continues its unstoppable ascension: after being recently recognized by Cofepris, Mexico’s sanitary agency, as an authorized laboratory to assess biotech treatments entering the Mexican market, UDIBI has no started to develop its own, innovative compounds. Sonia Mayra Peréz Tapia, executive director of UDIBI, highlights the ambitious…
Luxembourg CEO Marc Vandelaer reveals why the Luxembourg biobank IBBL is more than a traditional biobank and how, despite the short time since its inception in 2010, it has begun to receive recognition as a leader within the biobanking industry and a valued bioservice provider. IBBL (Integrated BioBank of Luxembourg) has…
Amgen Established in November 2014, Amgen’s Next-Generation Biomanufacturing facility in Singapore heralds a new juncture of efficient and innovative commercial-scale production of medicines. VP of Singapore Site Operations, Arleen Paulino, pinpoints the elements that distinguish this facility from current standards in manufacturing, while highlighting the key role that this facility will…
Singapore With Amgen having recently reacquired the sales rights to three of its drugs, the company’s GM in Singapore and Malaysia, Raphael Ho, explains the rationale behind Amgen’s recent entry in Singapore and his experience in setting up the affiliate, while also expounding upon the unique value of Amgen products in…
Merck Asanga Halangoda, Director of Life Science at Merck Philippines, discusses the company’s impressive recent market performance, the importance of innovation in maintaining product pipeline, and the bright future of the affiliate’s role in the company’s emerging market portfolio. As an introduction to our readers, could you please give us an…
Biotech Ronald Scott, CEO of Basilea, a biotech company that was spun out of Roche in 2000, talks about launching its first two products, Zevtera and Cresemba; the milestone agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop Zevtera for the US market; and about the company’s partnering…
Ireland Noel Heaney, general manager of BMS Biologics Ireland, provides an overview of BMS in Ireland, its exciting new USD 900 million biologics facility in Cruiserath, their innovative HR programs and his five-year-vision for BMS Biologics in Ireland. BMS has a strong heritage in Ireland dating back to 1964 when it…
Hungary Hungary’s medicinal biotech companies are clustered in the country’s four major university towns: Budapest, Debrecen, Szeged and Pécs, with the majority basing themselves in the capital, Budapest. Click here to read more articles and interviews from Hungary
Pharma Singapore, though conscious of its limitations, has been able to leverage its key assets of location, infrastructure and local talent in order to become the business hub for the entire region, with pharma and biotech as key components in its success. Singapore is … an attractive investment destination, especially for the…
Pharma With nearly €4 billion of capital investment in large molecule manufacturing underway, Ireland’s strategy to become a premier destination for biologics FDI has proven to be successful, according to BioPharmaChem Ireland director Matt Moran. Yet, Ireland today is much more than a manufacturing hub, and is well on its way to…
See our Cookie Privacy Policy Here
